剂泰科技-P今日盘中股价大涨179.05%，引起了市场的广泛关注。此次剧烈波动发生在该股于港交所主板的首个交易日。
消息面上，股价飙升的主要原因在于其首次公开募股（IPO）获得了市场的狂热追捧。根据配发结果，剂泰科技-P的香港公开发售部分获得了约6910.96倍的超额认购，锁定认购资金超过7300亿港元，成为2026年迄今港股医疗健康板块IPO的“冻资王”。极高的超额认购倍数和一手中签率低至0.14%，反映了市场资金对其“AI药物递送第一股”独特定位及技术前景的强烈信心。
此外，公司此次IPO引入了包括贝莱德、瑞银、高瓴、未来资产等在内的18家知名基石投资者，合计认购约1.48亿美元，进一步巩固了市场对其长期价值的认可。公司自主开发的AI驱动纳米药物递送平台NanoForge及其产品管线，也被视为其在生物科技领域的重要竞争优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.